The gist

Forces drugmakers to share consistent info between the Food and Drug Administration (FDA) and Patent Office, aiming to curb patent tricks that keep drug prices high.

Who wins, who loses

• Wins: patients paying high drug prices, generic drugmakers, insurers trying to lower costs.
• Loses: brand-name pharmaceutical companies that rely on long patent protections to maximize profits.

What it does

• Requires drug and biologic sponsors to certify their FDA and United States Patent and Trademark Office (USPTO) submissions match.
• Mandates sharing patentability-related info (analytical data, prior art statements) between both agencies.
• Adds a new court defense: accused infringers can escape liability if the patent holder hid required info.
• Protects trade secrets, but USPTO can disclose info needed to understand patent scope.

Why should I care?

Prescription drug prices in the US are among the world's highest. Supporters say drugmakers exploit inconsistent disclosures to extend monopolies and block generics. Critics argue the extra paperwork burdens innovation and that trade secrets risk exposure. Where do you land? Vote below and use "Tell Your Rep" to make sure your voice reaches Congress.